Literature DB >> 3077281

Penicillin-binding proteins and beta-lactamases: their effects on the use of cephalosporins and other new beta-lactams.

H C Neu.   

Abstract

Alteration of PBPs has proved an effective way for gram-positive bacteria to become resistant to beta-lactams. The gram-positive species have not been able to use decreased permeability or synthesis of novel beta-lactamases to overcome the advances by medicinal chemists. Nonetheless, altered PBPs have proved to be a formidable form of resistance for staphylococci, enterococci, and even some S. pneumoniae. Although isolated examples of resistance of gram-negative species to beta-lactams have been seen for E. coli, Serratia, or P. aeruginosa, in general this form of resistance has not been used by the gram-negative species except by N. gonorrhoeae. Conversely gram-negative bacteria have used beta-lactamases as an effective weapon to overcome the advances in medical chemistry that have provided beta-lactamase inhibitors and structurally stable cephalosporins, monobactams, and carbapenems. Derepression or induction of beta-lactamases has provided species such as E. cloacae and P. aeruginosa the ability to resist destruction by new cephalosporins. The original concept of beta-lactamase as a trap or sponge has been shown to be inaccurate, and we realize that the high concentration of beta-lactamase in the periplasmic space combined with a decreased or slow entry of the beta-lactam allows an efficient acylation of the so-called stable cephalosporins with hydrolysis of these compounds. Although the PBPs and beta-lactamases are clear problems, there is the potential for future modification of beta-lactam structures to increase affinity to PBPs and decrease beta-lactamase affinity. Bacterial populations do have the ability to create transferable resistance even to extended spectrum beta-lactams. It will be necessary to carefully monitor the development of resistance to new beta-lactams. However, advances in the chemistry of beta-lactams should offer solutions to these real but potentially controllable problems.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3077281

Source DB:  PubMed          Journal:  Curr Clin Top Infect Dis        ISSN: 0195-3842


  7 in total

1.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

2.  Pharmacodynamic effects of meropenem on gram-negative bacteria.

Authors:  H Hanberger; E Svensson; L E Nilsson; M Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

3.  Effective treatment of cephalosporin-rifampin combinations against cryptic methicillin-resistant beta-lactamase-producing coagulase-negative staphylococcal experimental endocarditis.

Authors:  C M Brandt; M S Rouse; B M Tallan; N W Laue; W R Wilson; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

4.  Evaluating the Effect of Oxygen Concentrations on Antibiotic Sensitivity, Growth, and Biofilm Formation of Human Pathogens.

Authors:  Shilpi Gupta; Nozrin Laskar; Daniel E Kadouri
Journal:  Microbiol Insights       Date:  2016-11-16

5.  Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.

Authors:  Dong Zhang; Marios S Markoulides; Dmitrijs Stepanovs; Anna M Rydzik; Ahmed El-Hussein; Corentin Bon; Jos J A G Kamps; Klaus-Daniel Umland; Patrick M Collins; Samuel T Cahill; David Y Wang; Frank von Delft; Jürgen Brem; Michael A McDonough; Christopher J Schofield
Journal:  Bioorg Med Chem       Date:  2018-02-23       Impact factor: 3.641

6.  Induction of the Stringent Response Underlies the Antimicrobial Action of Aliphatic Isothiocyanates.

Authors:  Dariusz Nowicki; Klaudyna Krause; Patrycja Szamborska; Adrianna Żukowska; Grzegorz M Cech; Agnieszka Szalewska-Pałasz
Journal:  Front Microbiol       Date:  2021-01-14       Impact factor: 5.640

7.  Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.

Authors:  A Oliver; M Pérez-Vázquez; M Martínez-Ferrer; F Baquero; L De Rafael; R Cantón
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.